Jonas Bergh

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. doi request reprint FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer
    Jonas Bergh
    Karolinska Institutet, Stockholm, Sweden
    J Clin Oncol 30:1919-25. 2012
  2. doi request reprint First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study
    Jonas Bergh
    Karolinska Institutet and University Hospital, 171 76 Stockholm, Sweden
    J Clin Oncol 30:921-9. 2012
  3. pmc Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
    Stefano Calza
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobel väg 12A, SE 171 77 Stockholm, Sweden
    Breast Cancer Res 8:R34. 2006
  4. doi request reprint Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer
    Jonas Bergh
    Karolinska Institutet and University Hospital, Stockholm, Sweden
    Breast 21:507-13. 2012
  5. doi request reprint Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer
    Annelie Liljegren
    Karolinska Institutet and Karolinska University Hospital, SE 171 76, Stockholm, Sweden
    Breast 18:259-62. 2009
  6. doi request reprint Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels
    Mariann Iiristo
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Acta Oncol 50:338-43. 2011
  7. doi request reprint Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
    Theodoros Foukakis
    Department of Oncology Pathology, Radiumhemmet, Karolinska Institutet, Karolinska University Hospital, 17176 Stockholm, Sweden
    Breast Cancer Res Treat 130:553-60. 2011
  8. doi request reprint Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer
    Asgerdur Sverrisdottir
    Department of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden
    Breast Cancer Res Treat 128:755-63. 2011
  9. pmc The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer
    Gustaf Rosin
    Department of Biosciences and Nutrition, Novum, and Science for Life Laboratory, Karolinska Institutet, Hälsovägen 7, Huddinge, Sweden
    BMC Cancer 12:79. 2012
  10. doi request reprint Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden
    Ulla Wilking
    Karolinska Institutet, Department of Oncology Pathology, Stockholm, Sweden
    Acta Oncol 49:844-50. 2010

Collaborators

Detail Information

Publications32

  1. doi request reprint FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer
    Jonas Bergh
    Karolinska Institutet, Stockholm, Sweden
    J Clin Oncol 30:1919-25. 2012
    ..To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer...
  2. doi request reprint First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study
    Jonas Bergh
    Karolinska Institutet and University Hospital, 171 76 Stockholm, Sweden
    J Clin Oncol 30:921-9. 2012
    ..To investigate whether sunitinib plus docetaxel improves clinical outcomes for patients with human epidermal growth factor receptor 2 (HER2)/neu-negative advanced breast cancer (ABC) versus docetaxel alone...
  3. pmc Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
    Stefano Calza
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobel väg 12A, SE 171 77 Stockholm, Sweden
    Breast Cancer Res 8:R34. 2006
    ..So far, however, they have not superseded routine histopathology and staging criteria, partly because the few studies performed on molecular subtyping have had little validation and limited clinical characterization...
  4. doi request reprint Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer
    Jonas Bergh
    Karolinska Institutet and University Hospital, Stockholm, Sweden
    Breast 21:507-13. 2012
    ..This exploratory study examined the pharmacokinetics, safety, and antitumor activity of sunitinib plus docetaxel in patients with HER-2-negative advanced breast cancer...
  5. doi request reprint Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer
    Annelie Liljegren
    Karolinska Institutet and Karolinska University Hospital, SE 171 76, Stockholm, Sweden
    Breast 18:259-62. 2009
    ..The current report describes four patients with advanced/metastatic breast cancer who experienced clinically meaningful responses following treatment with sunitinib in combination with docetaxel...
  6. doi request reprint Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels
    Mariann Iiristo
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Acta Oncol 50:338-43. 2011
    ....
  7. doi request reprint Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
    Theodoros Foukakis
    Department of Oncology Pathology, Radiumhemmet, Karolinska Institutet, Karolinska University Hospital, 17176 Stockholm, Sweden
    Breast Cancer Res Treat 130:553-60. 2011
    ..Treatment advancements in MBC are not reflected by better survival for the whole MBC population. An improvement is only observed after the year 2000 and is restricted to younger patients...
  8. doi request reprint Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer
    Asgerdur Sverrisdottir
    Department of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden
    Breast Cancer Res Treat 128:755-63. 2011
    ..The combination of goserelin and tamoxifen is not superior to either modality alone. With the limitations of a subset trial, these data have to be interpreted cautiously...
  9. pmc The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer
    Gustaf Rosin
    Department of Biosciences and Nutrition, Novum, and Science for Life Laboratory, Karolinska Institutet, Hälsovägen 7, Huddinge, Sweden
    BMC Cancer 12:79. 2012
    ..This study was undertaken to assess the prognostic value and therapy-predictive potential of DYX1C1 mRNA and protein expression in breast cancer...
  10. doi request reprint Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden
    Ulla Wilking
    Karolinska Institutet, Department of Oncology Pathology, Stockholm, Sweden
    Acta Oncol 49:844-50. 2010
    ..Patients with BC are treated within each of the six different Health Care Regions (HCRs) in Sweden. This aim of this project was to study the introduction and usage of trastuzumab in BC in the six HCRs in Sweden...
  11. doi request reprint A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
    Sara Margolin
    Department of Oncology, Karolinska Institute and University Hospital, Stockholm, Sweden
    Acta Oncol 50:35-41. 2011
    ..Discussion. Dose-dense and tailored EC/T can be given with manageable toxicity and is after adjustment presently studied in the phase III Panther trial...
  12. ncbi request reprint How to treat male breast cancer
    Kamila Czene
    Department of Medical Epidemiology and Biostatistics MEB, Karolinska Institutet, Stockholm, Sweden
    Breast 16:S147-54. 2007
    ..Different chemotherapy regimens have been used in the adjuvant and metastatic setting. The use of adjuvant therapy has in institutional and review comparisons been demonstrated to result in an improved outcome...
  13. pmc Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies
    Jelena Milosević
    Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm S 171 76, Sweden
    BMC Cancer 13:473. 2013
    ..We aimed to address this knowledge gap in order to enhance our understanding of endocrine therapy resistance in breast cancer patients...
  14. pmc A simple method for assigning genomic grade to individual breast tumours
    Kristian Wennmalm
    Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Cancer Centrum Karolinska, R8 3, 171 76 Stockholm, Sweden
    BMC Cancer 11:306. 2011
    ..Here, we investigate the performance of a method that uses no information outside the breast profile of interest...
  15. pmc Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
    Håkan Norell
    Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
    J Transl Med 8:53. 2010
    ..Here we report the first administration of a Her2-plasmid DNA (pDNA) vaccine in humans...
  16. ncbi request reprint Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers
    Barbro Linderholm
    Department of Oncology and Pathology, CCK Cancer Centrum Karolinska, Karolinska Institutet and Hospital, SE 171 76 Stockholm, Sweden
    Eur J Cancer 40:2417-23. 2004
    ..009), but there was no correlation between this p53 group and those with low TSP-1 levels (P=0.2). In conclusion, TSP-1 expression was not prognostic and was not associated with neither p53-status or VEGF expression...
  17. doi request reprint Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
    Mahmoud R Khoshnoud
    Department of Oncology, Karolinska University Hospital, Karolinska Institute, Sodersjukhuset, 11883, Stockholm, Sweden
    Breast Cancer Res Treat 126:421-30. 2011
    ..001; cytosol: HR, 0.53, P < 0.001). The effect on overall survival was not statistically significant probably due to the limited sample size. Both IHC and cytosol assay accurately predict long-term response to adjuvant tamoxifen...
  18. doi request reprint HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
    Ulla Wilking
    Department of Oncology Pathology, Karolinska Institutet and Cancer Center Karolinska, Stockholm, Sweden
    Breast Cancer Res Treat 125:553-61. 2011
    ..Overall survival HR is 5.47 (95% CI 2.01-14.91) and survival from relapse HR is 3.22 (95% CI 1.18-8.77). The unstable status for HER2 in breast cancer is clinically significant and should motivate more frequent testing of recurrences...
  19. ncbi request reprint Incidence and prognosis of synchronous and metachronous bilateral breast cancer
    Mikael Hartman
    Department of Medical Epidemiology and Biostatistics, Stockholm Söder Hospital and Oncologic Center, CLINTEC, Stockholm, Sweden
    J Clin Oncol 25:4210-6. 2007
    ..Little is known, however, about incidence trends and prognostic features of bilateral breast cancer...
  20. ncbi request reprint Adjuvant chemotherapy for breast cancer--"one fits all"?
    Jonas Bergh
    Stockholm Oncology, Radiumhemmet, Karolinska Institute and Karolinska University Hospital, SE 171 76 Stockholm, Sweden
    Breast 14:564-9. 2005
    ..Taken together these strategies will be very different from the present "one fits all" concept...
  21. ncbi request reprint Low concordance of biomarkers in histopathological and cytological material from breast cancer
    Gustav Stålhammar
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden Department of Clinical Pathology, Karolinska University Hospital, Stockholm, Sweden
    Histopathology 64:971-80. 2014
    ..The aim of this study was to investigate in primary breast cancer the congruency of routine clinical predictive biomarker evaluations, including ER, PR and Ki67, obtained using immunocytochemistry (ICC) and immunohistochemistry (IHC)...
  22. ncbi request reprint Superficial scrapings from breast tumors is a source for biobanking and research purposes
    Ran Ma
    Departments of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
    Lab Invest 94:796-805. 2014
    ..In conclusion, this method opens up a new possibility for usage of valuable fresh tumor material for research purposes, biobanking, and next-generation sequencing. ..
  23. doi request reprint Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling
    Oliver Frings
    Stockholm Bioinformatics Centre, Science for Life Laboratory, Solna, Sweden
    Am J Pathol 182:2037-47. 2013
    ....
  24. pmc Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
    Shahab Akhoondi
    Departments of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden
    Breast Cancer Res 12:R105. 2010
    ..Mutational inactivation of the FBXW7/hCDC4 tumor suppressor gene (TSG) is common in many cancer types, but infrequent in breast cancers. This study investigates the presence and impact of FBXW7/hCDC4 promoter methylation in breast cancer...
  25. ncbi request reprint Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypes
    Kristian Wennmalm
    Department of Oncology and Pathology, Cancer Center Karolinska, Radiumhemmet, Karolinska Institutet and University Hospital, Stockholm, Sweden
    Genes Chromosomes Cancer 46:87-97. 2007
    ..This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat...
  26. ncbi request reprint Sequencing of the tumor suppressor gene TP 53
    Barbro Linderholm
    Radiumhemmet, Karolinska Institute and Hospital, Stockholm, Sweden
    Methods Mol Med 120:389-401. 2006
    ..This chapter describes protocols for the 'gold standard', but perhaps complex and time consuming, methods for sequencing TP 53, by cDNA and genomic based sequencing techniques...
  27. ncbi request reprint Different methods for the detection of small changes in uptake between single-photon emission computed tomography (SPECT) examinations: 99mTc-sestamibi in chemotherapy for breast tumours
    Hans Jacobsson
    Department of Radiology, Karolinska University Hospital, Stockholm, Sweden
    Nucl Med Commun 27:347-52. 2006
    ..For this purpose, we employed a patient cohort from a previous study assessing the response to neoadjuvant chemotherapy for breast cancer using Tc-hexakis-2-methoxyisobutylisonitrile (Tc-sestamibi)...
  28. ncbi request reprint Improvements in patient satisfaction at an outpatient clinic for patients with breast cancer
    Mia Bergenmar
    Department of Oncology Pathology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Acta Oncol 45:550-8. 2006
    ..In conclusion, the questionnaire captured positive changes in patient satisfaction between the two measurements. Further changes for the better were still requested concerning continuity of care despite reported improvement...
  29. pmc Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer
    Janna Paulsson
    Department of Oncology Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
    Am J Pathol 175:334-41. 2009
    ..These findings highlight the prognostic significance of stromal markers and should be considered in ongoing clinical development of PDGF receptor inhibitors...
  30. pmc Forecasting drug utilization and expenditure in a metropolitan health region
    Björn Wettermark
    Department of Drug Management and Informatics, Stockholm County Council, Stockholm, Sweden
    BMC Health Serv Res 10:128. 2010
    ..The aim of this paper is to present the forecasting model and the predicted growth in all therapeutic areas in 2010 and 2011...
  31. ncbi request reprint HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components
    Jenny Andersson
    Department of Oncology, Radiumhemmet, Karolinska Institute and Hospital, Stockholm, Sweden
    Appl Immunohistochem Mol Morphol 12:14-20. 2004
    ..Perhaps the intratumor HER-2/neu heterogeneity can explain some of the unexpected failures of trastuzumab therapy...
  32. ncbi request reprint Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers
    Barbro K Linderholm
    Department of Oncology, Radiumhemmet, Karolinska Institute and Hospital, SE 161 67 Stockholm, Sweden
    Clin Breast Cancer 4:340-7. 2003
    ..The results might implicate that different angiogenic pathways exist in human breast cancer...